Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Deferred Taxes of $9.3 million for Q1 2026, up 134.27% on a QoQ basis from -$27.2 million in Q4 2025, and down 3.41% year-over-year from $9.6 million in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Deferred Taxes history runs 5 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- Quarterly Deferred Taxes fell 3.41% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (up 97.41% YoY) and the FY2025 annual result came in at -$2.2 million, up 97.94% from the prior year.
- Deferred Taxes was $9.3 million for Q1 2026 at Alnylam Pharmaceuticals, up from -$27.2 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $9.7 million in Q2 2025 and bottomed at -$107.4 million in Q4 2024.
- A 3-year average of -$11.1 million and a median of $454000.0 in 2024 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2025 — Deferred Taxes jumped 3534.36% — and 2026, when it slipped 3.41%.
- Alnylam Pharmaceuticals' Deferred Taxes stood at -$107.4 million in 2024, then soared by 74.7% to -$27.2 million in 2025, then soared by 134.27% to $9.3 million in 2026.
- Business Quant data shows ALNY's Deferred Taxes at $9.3 million in Q1 2026, -$27.2 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.31 Mn |
| Dec 31, 2025 | -27.17 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 9.74 Mn |
| Mar 31, 2025 | 9.64 Mn |
| Dec 31, 2024 | -107.39 Mn |
| Sep 30, 2024 | -163,000.00 |
| Jun 30, 2024 | 340,000.00 |
| Mar 31, 2024 | 454,000.00 |
| Dec 31, 2010 | 10.88 Mn |
| Sep 30, 2010 | 83,000.00 |
| Jun 30, 2010 | -85,000.00 |
| Mar 31, 2010 | -131,000.00 |
| Dec 31, 2009 | -5.19 Mn |
| Sep 30, 2009 | 281,000.00 |